Study Complete
Sponsor ID
20030207
A Study of Darbepoetin Alfa in Anemic Subjects with Low Risk Myelodysplastic Syndrome
Study Details
The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).
Protocol Summary
Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available
Locations
No locations found.